NEW YORK--(BUSINESS WIRE)--IRX Therapeutics, a privately-held company dedicated to the discovery and development of proprietary therapies for the treatment of cancer and viral diseases, today announced preliminary findings from its Phase 2 clinical trial of IRX-2, the Company’s investigational immunotherapy for head & neck cancer.
